Skip to main content

Singer Nicholas Jason's Form 4 filing

Ernexa Therapeutics Inc. (ERNA) · filed Dec 6, 2022

Accession no.
0001140361-22-044631
Filed
Dec 6, 2022, 6:52 PM ET
Trade date
Dec 2, 2022
Filing delay
4 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 2 non-derivative transactions and 2 derivative transactions. Open-market purchases total $929.2K. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Singer Nicholas JasonCIK 0001828224Director

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Dec 2, 2022Common StockPPurchaseAcquired+70,822$3.28+$232,296.16121,822Indirect
Dec 2, 2022Common StockPPurchaseAcquired+212,464$3.28+$696,881.92266,214Indirect

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Dec 2, 2022Common Stock, par value $0.005 per sharePPurchaseAcquired+141,644$0.125+$17,705.5141,644Indirect
Dec 2, 2022Common Stock, par value $0.005 per sharePPurchaseAcquired+424,928$0.125+$53,116424,928Indirect

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)